Odyssey Therapeutics, Inc. (ODTX) – What Are Researchers Saying About This Stock?

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $35.33.

ODTX has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings started coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. HC Wainwright assumed coverage on Odyssey Therapeutics in a report on Thursday, August 27th. They issued a “buy” rating and a $44.00 price objective for the company. Raymond James Financial started coverage on shares of Odyssey Therapeutics in a research note on Thursday, October 8th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, UBS Group started coverage on shares of Odyssey Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $27.00 target price for the company.

Odyssey Therapeutics Stock Performance

ODTX stock opened at $19.83 on Friday. The stock has a 50 day moving average of $21.90. The company has a market capitalization of $953.03 million and a PE ratio of -2.93. Odyssey Therapeutics has a 1-year low of $15.10 and a 1-year high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. Equities analysts anticipate that Odyssey Therapeutics will post -6.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Odyssey Therapeutics

Several institutional investors have recently bought and sold shares of the business. State Street Corp bought a new position in shares of Odyssey Therapeutics during the 2nd quarter valued at approximately $1,477,000. The Manufacturers Life Insurance Company bought a new position in Odyssey Therapeutics in the 2nd quarter worth about $601,000. Finally, Citadel Advisors LLC purchased a new position in Odyssey Therapeutics during the 2nd quarter worth $4,162,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.